Mid-Regional pro-adrenomedullin in acute heart failure: A better biomarker or just another biomarker

Current Heart Failure Reports

Volumn 9, Issue 3, 2012, Pages 244-251

  Potocki, Mihael ^a   Ziller, Ronny ^a   Mueller, Christian ^a  

^a UNIVERSITY HOSPITAL BASEL   (Switzerland)

Author keywords

Adrenomedullin; Biomarkers; Heart failure; MR proADM; Prognosis

Indexed keywords

PROADRENOMEDULLIN; ADRENOMEDULLIN; BIOLOGICAL MARKER; BRAIN NATRIURETIC PEPTIDE; MID REGIONAL PRO ADRENOMEDULLIN, HUMAN; MID-REGIONAL PRO-ADRENOMEDULLIN, HUMAN; PEPTIDE FRAGMENT; PROTEIN PRECURSOR;

ACUTE CORONARY SYNDROME; ACUTE HEART FAILURE; ACUTE HEART INFARCTION; ARTICLE; CARDIAC PATIENT; CARDIOVASCULAR RISK; CARDIOVASCULAR SYSTEM; CIRCULATION; CORONARY ARTERY BLOOD FLOW; HEART FAILURE; HUMAN; PROGNOSIS; PROTEIN FUNCTION; PROTEIN SYNTHESIS; RISK MANAGEMENT; ACUTE DISEASE; CHRONIC DISEASE; HEART INFARCTION; METABOLISM; MORTALITY; PHYSIOLOGY; REVIEW; VASCULAR ENDOTHELIUM; VASODILATATION;

ACUTE CORONARY SYNDROME; ACUTE DISEASE; ADRENOMEDULLIN; BIOLOGICAL MARKERS; CHRONIC DISEASE; ENDOTHELIUM, VASCULAR; HEART FAILURE; HUMANS; MYOCARDIAL INFARCTION; NATRIURETIC PEPTIDE, BRAIN; PEPTIDE FRAGMENTS; PROGNOSIS; PROTEIN PRECURSORS; VASODILATION;

EID: 84871859337     PISSN: 15469530     EISSN: 15469549     Source Type: Journal    
DOI: 10.1007/s11897-012-0096-6     Document Type: Article

References (71)

1. Biomarkers and surrogate endpoints: preferred definitions and conceptual framework. Clin Pharmacol Ther. 2001;69:89-95.
2. Maisel AS, Krishnaswamy P, Nowak RM, McCord J, Hollander JE, Duc P, Omland T, Storrow AB, Abraham WT, Wu AH, Clopton P, Steg PG, Westheim A, Knudsen CW, Perez A, Kazanegra R, Herrmann HC, McCullough PA. Rapid measurement of b-type natriuretic peptide in the emergency diagnosis of heart failure. N Engl J Med. 2002;347:161-7. (Pubitemid 34764819)
3. Januzzi Jr. JL, Sakhuja R, O'DonoghueM, Baggish AL, Anwaruddin S, Chae CU, Cameron R, Krauser DG, Tung R, Camargo Jr. CA, Lloyd-Jones DM. Utility of amino-terminal pro-brain natriuretic peptide testing for prediction of 1-year mortality in patients with dyspnea treated in the emergency department. Arch Intern Med. 2006;166:315-20. (Pubitemid 43244319)
4. Peacock WFt, De Marco T, Fonarow GC, Diercks D, Wynne J, Apple FS, Wu AH. Cardiac troponin and outcome in acute heart failure. N Engl J Med. 2008;358:2117-26. (Pubitemid 351679598)
5. Weinberg EO, Shimpo M, Hurwitz S, Tominaga S, Rouleau JL, Lee RT. Identification of serum soluble st2 receptor as a novel heart failure biomarker. Circulation. 2003;107:721-6. (Pubitemid 36222600)
6. Morrow DA, de Lemos JA. Benchmarks for the assessment of novel cardiovascular biomarkers. Circulation. 2007;115:949-52. (Pubitemid 46328287)
7. Nakamura M, Yoshida H, Makita S, Arakawa N, Niinuma H, Hiramori K. Potent and long-lasting vasodilatory effects of adrenomedullin in humans. Comparisons between normal subjects and patients with chronic heart failure. Circulation. 1997;95:1214-21. (Pubitemid 27097833)
8. Kitamura K, Kangawa K, Kawamoto M, Ichiki Y, Nakamura S, Matsuo H, Eto T. Adrenomedullin: a novel hypotensive peptide isolated from human pheochromocytoma. Biochem Biophys Res Commun. 1993;192:553-60. (Pubitemid 23227359)
9. Nicholls MG, Charles CJ, Lainchbury JG, Lewis LK, Rademaker MT, Richards AM, Yandle TG. Adrenomedullin in heart failure. Hypertens Res. 2003;26(Suppl):S135-40. (Pubitemid 36372329)
10. Kato J, Kobayashi K, Etoh T, Tanaka M, Kitamura K, Imamura T, Koiwaya Y, Kangawa K, Eto T. Plasma adrenomedullin concentration in patients with heart failure. J Clin Endocrinol Metab. 1996;81:180-3. (Pubitemid 26035022)
11. Richards AM, Nicholls MG, Yandle TG, Frampton C, Espiner EA, Turner JG, Buttimore RC, Lainchbury JG, Elliott JM, Ikram H, Crozier IG, Smyth DW. Plasma n-terminal pro-brain natriuretic peptide and adrenomedullin: new neurohormonal predictors of left ventricular function and prognosis after myocardial infarction. Circulation. 1998;97:1921-9.
12. Hinson JP, Kapas S, Smith DM. Adrenomedullin, a multifunctional regulatory peptide. Endocr Rev. 2000;21:138-67. (Pubitemid 32275593)
13. Struck J, Tao C, Morgenthaler NG, Bergmann A. Identification of an adrenomedullin precursor fragment in plasma of sepsis patients. Peptides. 2004;25:1369-72. (Pubitemid 39180069)
14. Khan SQ, O'Brien RJ, Struck J, Quinn P, Morgenthaler N, Squire I, Davies J, Bergmann A, Ng LL. Prognostic value of midregional pro-Adrenomedullin in patients with acute myocardial infarction: the lamp (leicester acute myocardial infarction peptide) study. J Am Coll Cardiol. 2007;49:1525-32. (Pubitemid 46517963)
15. Gegenhuber A, Struck J, Dieplinger B, Poelz W, Pacher R, Morgenthaler NG, Bergmann A, Haltmayer M, Mueller T. Comparative evaluation of b-type natriuretic peptide, mid-regional proa- type natriuretic peptide, mid-regional pro-Adrenomedullin, and copeptin to predict 1-year mortality in patients with acute destabilized heart failure. J Card Fail. 2007;13:42-9. (Pubitemid 46343794)
16. Behnes M, Papassotiriou J, Walter T, Fiedler E, Sauer T, Lang S, Elmas E, Hoffmann U, Borggrefe M, Brueckmann M. Long-term prognostic value of mid-regional pro-Adrenomedullin and cterminal pro-endothelin-1 in patients with acute myocardial infarction. Clin Chem Lab Med. 2008;46:204-11.
17. Adlbrecht C, Hulsmann M, Strunk G, Berger R, Mortl D, Struck J, Morgenthaler NG, Bergmann A, Jakowitsch J, Maurer G, Lang IM, Pacher R. Prognostic value of plasma midregional proadrenomedullin and c-terminal-pro-endothelin-1 in chronic heart failure outpatients. Eur J Heart Fail. 2009;11:361-6.
18. Gombos T, Forhecz Z, Pozsonyi Z, Wallentin S, Papassotiriou J, Kunde J, Morgenthaler NG, Janoskuti L, Prohaszka Z. Adrenomedullin and endothelin-1 are related to inflammation in chronic heart failure. Inflamm Res. 2009;58:298-305.
19. Potocki M, Breidthardt T, Reichlin T, Morgenthaler NG, Bergmann A, NoveanuM, Schaub N, Uthoff H, Freidank H, Buser L, Bingisser R, Christ M, Mebazaa A, Mueller C. Midregional proadrenomedullin in addition to b-type natriuretic peptides in the risk stratification of patients with acute dyspnea: an observational study. Crit Care. 2009;13:R122.
20. Masson S, Latini R, Carbonieri E, Moretti L, Rossi MG, Ciricugno S, Milani V, Marchioli R, Struck J, Bergmann A, Maggioni AP, Tognoni G, Tavazzi L, Investigators G-H. The predictive value of stable precursor fragments of vasoactive peptides in patients with chronic heart failure: data from the gissi-heart failure (gissi-hf) trial. Eur J Heart Fail. 2010;12:338-47.
21. von Haehling S, Filippatos GS, Papassotiriou J, Cicoira M, Jankowska EA, Doehner W, Rozentryt P, Vassanelli C, Struck J, Banasiak W, Ponikowski P, Kremastinos D, Bergmann A, Morgenthaler NG, Anker SD. Mid-regional pro-Adrenomedullin as a novel predictor of mortality in patients with chronic heart failure. Eur J Heart Fail. 2010;12:484-91.
22. Klip IT, Voors AA, Anker SD, Hillege HL, Struck J, Squire I, van Veldhuisen DJ, Dickstein K, OPTIMAAL Investigators. Prognostic value of mid-regional pro-Adrenomedullin in patients with heart failure after an acute myocardial infarction. Heart. 2011;97:892-8.
23. Maisel A, Mueller C, Nowak RM, Peacock WF, Ponikowski P, Mockel M, Hogan C, Wu AH, Richards M, Clopton P, Filippatos GS, Di Somma S, Anand I, Ng LL, Daniels LB, Neath SX, Christenson R, Potocki M, McCord J, Hartmann O, Morgenthaler NG, Anker SD. Midregion prohormone adrenomedullin and prognosis in patients presenting with acute dyspnea: results from the bach (biomarkers in acute heart failure) trial. J Am Coll Cardiol. 2011;58:1057-67. This prospective, multicenter, international study included 1,641 patients presenting to the emergency department with dyspnea. In the subgroup of 568 patients diagnosed with acute heart failure, MR-proADM was superior to BNP and NTproBNP for predicting 90-day mortality and especially 30-day mortality.
24. Peacock WF, Nowak R, Christenson R, DiSomma S, Neath SX, Hartmann O, Mueller C, Ponikowski P, Mockel M, Hogan C, Wu AH, Richards M, Filippatos GS, Anand I, Ng LL, Daniels LB, Morgenthaler N, Anker SD, Maisel AS. Short-term mortality risk in emergency department acute heart failure. Acad Emerg Med. 2011;18:947-58.
25. Maisel A, Mueller C, Nowak R, Peacock WF, Landsberg JW, Ponikowski P, Mockel M, Hogan C, Wu AH, Richards M, Clopton P, Filippatos GS, Di Somma S, Anand I, Ng L, Daniels LB, Neath SX, Christenson R, Potocki M, McCord J, Terracciano G, Kremastinos D, Hartmann O, von Haehling S, Bergmann A, Morgenthaler NG, Anker SD. Mid-region pro-hormone markers for diagnosis and prognosis in acute dyspnea: results from the bach (biomarkers in acute heart failure) trial. J Am Coll Cardiol. 2010;55:2062-76.
26. Shimosawa T, Fujita T. Adrenomedullin and its related peptide. Endocr J. 2005;52:1-10. (Pubitemid 40410312)
27. Kitamura K, Kangawa K, Ishiyama Y, Washimine H, Ichiki Y, Kawamoto M, Minamino N, Matsuo H, Eto T. Identification and hypotensive activity of proadrenomedullin n-terminal 20 peptide (pamp). FEBS Lett. 1994;351:35-7. (Pubitemid 24268060)
28. Watanabe TX, Itahara Y, Inui T, Yoshizawa-Kumagaye K, Nakajima K, Sakakibara S. Vasopressor activities of n-terminal fragments of adrenomedullin in anesthetized rat. Biochem Biophys Res Commun. 1996;219:59-63. (Pubitemid 26071603)
29. Gumusel B, Hao Q, Hyman AL, Kadowitz PJ, Champion HC, Chang JK, Mehta JL, Lippton H. Analysis of responses to adrenomedullin-(13-52) in the pulmonary vascular bed of rats. Am J Physiol. 1998;274:H1255-63.
30. Poyner DR, Sexton PM, Marshall I, Smith DM, Quirion R, Born W, Muff R, Fischer JA, Foord SM. International union of pharmacology. Xxxii. The mammalian calcitonin gene-related peptides, adrenomedullin, amylin, and calcitonin receptors. Pharmacol Rev. 2002;54:233-46. (Pubitemid 34575714)
31. Lopez J, Martinez A. Cell and molecular biology of the multifunctional peptide, adrenomedullin. Int Rev Cytol. 2002;221:1-92. (Pubitemid 35429860)
32. Tomoda Y, Isumi Y, Katafuchi T, Minamino N. Regulation of adrenomedullin secretion from cultured cells. Peptides. 2001;22:1783-94. (Pubitemid 34062795)
33. Zhou M, Chaudry IH, Wang P. The small intestine is an important source of adrenomedullin release during polymicrobial sepsis. Am J Physiol Regul Integr Comp Physiol. 2001;281:R654-60.
34. Zhou M, Chaudry IH, Wang P. Adrenomedullin is upregulated in the heart and aorta during the early and late stages of sepsis. Biochim Biophys Acta. 1999;1453:273-83. (Pubitemid 29092765)
35. Washimine H, Asada Y, Kitamura K, Ichiki Y, Hara S, Yamamoto Y, Kangawa K, Sumiyoshi A, Eto T. Immunohistochemical identification of adrenomedullin in human, rat, and porcine tissue. Histochem Cell Biol. 1995;103:251-4.
36. Ishimitsu T, Miyata A, Matsuoka H, Kangawa K. Transcriptional regulation of human adrenomedullin gene in vascular endothelial cells. Biochem Biophys Res Commun. 1998;243:463-70. (Pubitemid 28414047)
37. Sugo S, Minamino N, Kangawa K, Miyamoto K, Kitamura K, Sakata J, Eto T, Matsuo H. Endothelial cells actively synthesize and secrete adrenomedullin. Biochem Biophys Res Commun. 1994;201:1160-6. (Pubitemid 24234212)
38. Meeran K, O'Shea D, Upton PD, Small CJ, Ghatei MA, Byfield PH, Bloom SR. Circulating adrenomedullin does not regulate systemic blood pressure but increases plasma prolactin after intravenous infusion in humans: a pharmacokinetic study. J Clin Endocrinol Metab. 1997;82:95-100. (Pubitemid 27021277)
39. Lewis LK, Smith MW, Yandle TG, Richards AM, Nicholls MG. Adrenomedullin(1-52) measured in human plasma by radioimmunoassay: plasma concentration, adsorption, and storage. Clin Chem. 1998;44:571-7. (Pubitemid 28141354)
40. Morgenthaler NG, Struck J, Alonso C, Bergmann A. Measurement of midregional proadrenomedullin in plasma with an immunoluminometric assay. Clin Chem. 2005;51:1823-9. (Pubitemid 41368172)
41. Ishiyama Y, Kitamura K, Ichiki Y, Nakamura S, Kida O, Kangawa K, Eto T. Hemodynamic effects of a novel hypotensive peptide, human adrenomedullin, in rats. Eur J Pharmacol. 1993;241:271-3. (Pubitemid 23272891)
42. Jougasaki M, Stevens TL, Borgeson DD, Luchner A, Redfield MM, Burnett Jr. JC. Adrenomedullin in experimental congestive heart failure: cardiorenal activation. Am J Physiol. 1997;273: R1392-9.
43. Lainchbury JG, Troughton RW, Lewis LK, Yandle TG, Richards AM, Nicholls MG. Hemodynamic, hormonal, and renal effects of short-term adrenomedullin infusion in healthy volunteers. J Clin Endocrinol Metab. 2000;85:1016-20. (Pubitemid 32269342)
44. Tsuruda T, Kato J, Kitamura K, Kuwasako K, Imamura T, Koiwaya Y, Kangawa K, Eto T. Secretion of proadrenomedullin n-terminal 20 peptide from cultured neonatal rat cardiac cells. Life Sci. 2001;69:239-45. (Pubitemid 32523080)
45. Chun TH, Itoh H, Saito T, Yamahara K, Doi K, Mori Y, Ogawa Y, Yamashita J, Tanaka T, InoueM,MasatsuguK, Sawada N, Fukunaga Y, Nakao K. Oxidative stress augments secretion of endotheliumderived relaxing peptides, c-type natriuretic peptide and adrenomedullin. J Hypertens. 2000;18:575-80. (Pubitemid 30303488)
46. Chun TH, Itoh H, Ogawa Y, Tamura N, Takaya K, Igaki T, Yamashita J, Doi K, Inoue M, Masatsugu K, Korenaga R, Ando J, Nakao K. Shear stress augments expression of c-type natriuretic peptide and adrenomedullin. Hypertension. 1997;29:1296-302. (Pubitemid 27233180)
47. Cormier-Regard S, Nguyen SV, Claycomb WC. Adrenomedullin gene expression is developmentally regulated and induced by hypoxia in rat ventricular cardiac myocytes. J Biol Chem. 1998;273:17787-92. (Pubitemid 28355122)
48. Nishikimi T, Yoshihara F, Mori Y, Kangawa K, Matsuoka H. Cardioprotective effect of adrenomedullin in heart failure. Hypertens Res. 2003;26(Suppl):S121- 7. (Pubitemid 36372327)
49. Hirata Y, Hayakawa H, Suzuki Y, Suzuki E, Ikenouchi H, Kohmoto O, Kimura K, Kitamura K, Eto T, Kangawa K, et al. Mechanisms of adrenomedullin-induced vasodilation in the rat kidney.Hypertension. 1995;25:790-5.
50. Tsuruda T, Kato J, Kitamura K, Kuwasako K, Imamura T, Koiwaya Y, Tsuji T, Kangawa K, Eto T. Adrenomedullin: a possible autocrine or paracrine inhibitor of hypertrophy of cardiomyocytes. Hypertension. 1998;31:505-10.
51. Inatsu H, Sakata J, Shimokubo T, Kitani M, Nishizono M, Washimine H, Kitamura K, Kangawa K, Matsuo H, Eto T. Distribution and characterization of rat immunoreactive proadrenomedullin n-terminal 20 peptide (pamp) and the augmented cardiac pamp in spontaneously hypertensive rat. Biochem Mol Biol Int. 1996;38:365-72. (Pubitemid 26258435)
52. Romppanen H, Marttila M, Magga J, Vuolteenaho O, Kinnunen P, Szokodi I, Ruskoaho H. Adrenomedullin gene expression in the rat heart is stimulated by acute pressure overload: blunted effect in experimental hypertension. Endocrinology. 1997;138:2636-9. (Pubitemid 27215273)
53. Nishikimi T, Horio T, Sasaki T, Yoshihara F, Takishita S, Miyata A, Matsuo H, Kangawa K. Cardiac production and secretion of adrenomedullin are increased in heart failure. Hypertension. 1997;30:1369-75. (Pubitemid 27528077)
54. Niu P, Shindo T, Iwata H, Iimuro S, Takeda N, Zhang Y, Ebihara A, Suematsu Y, Kangawa K, Hirata Y, Nagai R. Protective effects of endogenous adrenomedullin on cardiac hypertrophy, fibrosis, and renal damage. Circulation. 2004;109:1789-94. (Pubitemid 38500683)
55. Kawai J, Ando K, Tojo A, Shimosawa T, Takahashi K, Onozato ML, Yamasaki M, Ogita T, Nakaoka T, Fujita T. Endogenous adrenomedullin protects against vascular response to injury in mice. Circulation. 2004;109:1147-53. (Pubitemid 38332619)
56. Jougasaki M, Wei CM, McKinley LJ, Burnett Jr. JC. Elevation of circulating and ventricular adrenomedullin in human congestive heart failure. Circulation. 1995;92:286-9.
57. Hamada M, Shigematsu Y, Kawakami H, Minamino N, Kangawa K, Matsuo H, Hiwada K. Increased plasma levels of adrenomedullin in patients with hypertrophic cardiomyopathy: its relation to endothelin-i, natriuretic peptides and noradrenaline. Clin Sci (Lond). 1998;94:21-8. (Pubitemid 28029804)
58. Lainchbury JG, Cooper GJ, Coy DH, Jiang NY, Lewis LK, Yandle TG, Richards AM, Nicholls MG. Adrenomedullin: a hypotensive hormone in man. Clin Sci (Lond). 1997;92:467-72. (Pubitemid 27214205)
59. Nagaya N, Satoh T, Nishikimi T, Uematsu M, Furuichi S, Sakamaki F, Oya H, Kyotani S, Nakanishi N, Goto Y, Masuda Y, Miyatake K, Kangawa K. Hemodynamic, renal, and hormonal effects of adrenomedullin infusion in patients with congestive heart failure. Circulation. 2000;101:498-503. (Pubitemid 30080863)
60. Bhandari SS, Davies JE, Struck J, Ng LL. Influence of confounding factors on plasma mid-regional pro-Adrenomedullin and midregional pro-A-type natriuretic peptide concentrations in healthy individuals. Biomarkers. 2011;16:281-7.
61. Li Y, Jiang C, Wang X, Zhang Y, Shibahara S, Takahashi K. Adrenomedullin is a novel adipokine: adrenomedullin in adipocytes and adipose tissues. Peptides. 2007;28:1129-43. (Pubitemid 46654447)
62. Shimosawa T, Ogihara T, Matsui H, Asano T, Ando K, Fujita T. Deficiency of adrenomedullin induces insulin resistance by increasing oxidative stress. Hypertension. 2003;41:1080-5. (Pubitemid 36548606)
63. Dieplinger B,Mueller T, Kollerits B, Struck J, Ritz E, von Eckardstein A, Haltmayer M, Kronenberg F, Group MS. Pro-A-type natriuretic peptide and pro-Adrenomedullin predict progression of chronic kidney disease: the mmkd study. Kidney Int. 2009;75:408-14.
64. Richards AM, Nicholls MG, Espiner EA, Lainchbury JG, Troughton RW, Elliott J, Frampton C, Turner J, Crozier IG, Yandle TG. B-type natriuretic peptides and ejection fraction for prognosis after myocardial infarction. Circulation. 2003;107:2786-92. (Pubitemid 36705987)
65. Heeschen C, Hamm CW, Mitrovic V, Lantelme NH, White HD. Nterminal pro-b-type natriuretic peptide levels for dynamic risk stratification of patients with acute coronary syndromes. Circulation. 2004;110:3206-12. (Pubitemid 39525067)
66. Morrow DA, de Lemos JA, Sabatine MS, Murphy SA, Demopoulos LA, DiBattiste PM, McCabe CH, Gibson CM, Cannon CP, Braunwald E. Evaluation of b-type natriuretic peptide for risk assessment in unstable angina/non-st-elevation myocardial infarction: B-type natriuretic peptide and prognosis in tactics-timi 18. J Am Coll Cardiol. 2003;41:1264-72. (Pubitemid 36438985)
67. Wild PS, Schnabel RB, Lubos E, Zeller T, Sinning CR, Keller T, Tzikas S, Lackner KJ, Peetz D, Rupprecht HJ, Bickel C, Morgenthaler NG, Papassotiriou J, Tiret L, Munzel T, Blankenberg S. Midregional proadrenomedullin for prediction of cardiovascular events in coronary artery disease: results from the atherogene study. Clin Chem. 2012;58:226-36.
68. Nishikimi T, Saito Y, Kitamura K, Ishimitsu T, Eto T, Kangawa K, Matsuo H, Omae T, Matsuoka H. Increased plasma levels of adrenomedullin in patients with heart failure. J Am Coll Cardiol. 1995;26:1424-31.
69. Richards AM, Doughty R, Nicholls MG, MacMahon S, Sharpe N, Murphy J, Espiner EA, Frampton C, Yandle TG. Plasma nterminal pro-brain natriuretic peptide and adrenomedullin: prognostic utility and prediction of benefit from carvedilol in chronic ischemic left ventricular dysfunction. Australia-new zealand heart failure group. J Am Coll Cardiol. 2001;37:1781-7. (Pubitemid 32499959)
70. Pousset F, Masson F, Chavirovskaia O, Isnard R, Carayon A, Golmard JL, Lechat P, Thomas D, Komajda M. Plasma adrenomedullin, a new independent predictor of prognosis in patients with chronic heart failure. Eur Heart J. 2000;21:1009-14. (Pubitemid 30312090)
71. Lee DS, Schull MJ, Alter DA, Austin PC, Laupacis A, Chong A, Tu JV, Stukel TA. Early deaths in patients with heart failure discharged from the emergency department: a population-based analysis. Circ Heart Fail. 2010;3:228-35.